
TOKYO -- Japan's push to triple its stockpile of anti-flu medicine Avigan for coronavirus treatment has proven a challenge as the lack of a raw ingredient from China forces Fujifilm Holdings to switch to a domestic supplier.
Lack of element from China spurs to push to find domestic suppliers
TOKYO -- Japan's push to triple its stockpile of anti-flu medicine Avigan for coronavirus treatment has proven a challenge as the lack of a raw ingredient from China forces Fujifilm Holdings to switch to a domestic supplier.
Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.